CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 352 enrolled
Drug / intervention
pantoprazole+bismuth+tetra+metro +1 moredrug
Likely dose
pantoprazole+bismuth+tetra+metro 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02547038
NCT02547038N/ACompleted

Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication

Kaohsiung Veterans General Hospital.·interventional·Posted Sep 11, 2015·Updated Jun 10, 2019

In Brief

A clinical study evaluating pantoprazole+bismuth+tetra+metro and (panto+amox+clar+metr)+(panto+amox) for Helicobacter Pylori Infection. Completed, enrolled 352 participants across 1 site.

Detailed Summary

Reverse hybrid therapy achieves a higher eradication rate than bismuth quadruple therapy remained unanswered.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 11, 2015
Enrollment StartFeb 1, 2015
Primary CompletionOct 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 10.8 years ago

Interventions

pantoprazole+bismuth+tetra+metrodrug

pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days

(panto+amox+clar+metr)+(panto+amox)drug

a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily